Eli Lilly’s Alzheimer’s drug candidate slowed cognitive decline by 35 percent in a phase 3 study, but the trial revealed some safety risks, including two deaths from brain swelling and nearly 1 in 4 participants experiencing amyloid-related imaging abnormalities.
Read the full post on Becker's Hospital Review - Healthcare News
